Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 29%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical-stage biopharmaceutical company with a promising pipeline in the areas of immunology, inflammation, and oncology. Positive updates from competitors or FDA alignment on a regulatory filing strategy may lead to a rise in the stock price. However, there are also risks, including clinical development risk, capital markets and dilution risk, and pricing risk, that may impact the company's success and stock performance.

Bears say

Gossamer Bio is a clinical-stage biopharmaceutical company that has recently reported disappointing Phase 3 data for its lead drug candidate, seralutinib, in pulmonary arterial hypertension (PAH). While the company remains hopeful about its sub-group analyses and potential path to approval, there are concerns about the drug's overall efficacy and market opportunity. In addition, the company is facing financial challenges and will likely require additional funding to reach commercialization, which could put pressure on its stock price.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of May 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.